 **Medical Articles**


> Source: FDA


**Topic: FDA approves first Factor XIa inhibitor for secondary stroke prevention**

The FDA has approved **Sunharbo (asundexian)**, the first Factor XIa inhibitor, to reduce the risk of recurrent ischemic stroke in adults following a recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). It is taken once daily alongside antiplatelet therapy.
Approval was supported by the phase 3 OCEANIC-STROKE trial involving 12,327 patients. Asundexian reduced the risk of recurrent ischemic stroke compared with placebo, without a significant increase in major bleeding overall.
**Clinical significance:** Factor XIa inhibition offers a new approach to preventing recurrent ischemic stroke by targeting the coagulation pathway. It may provide additional protection while maintaining a relatively low major-bleeding risk in appropriately selected patients.

**Link:** [https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk](https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk)

[@HakimApps_Guideline](https://t.me/HakimApps_Guideline)